Angioprotection: brain vessels’ protection in family medicine’s practice

##plugins.themes.bootstrap3.article.sidebar##

PDF (Русский)
Published: Nov 30, 2017
DOI: https://doi.org/10.30841/2307-5112.5(73).2017.123019
Keywords:
cerebrovascular disturbances, endothelial dysfunction, angioprotection, neuroprotection, L-arginine, Tivomax,

##plugins.themes.bootstrap3.article.main##

С. Г. Бурчинський
ГУ «Институт геронтологии имени Д.Ф. Чеботарева НАМН Украины», г. Киев, Ukraine

Abstract

In the present paper the role of cerebrovascular pathology in a modern medicine and particularly the role of endothelial dysfunction as a one of the main pathogenetical mechanisms of brain vessels’ disturbances and ischemia of central nervous system has been  looked. Based on this point of view, the requirements to choice of optimal pharmacological strategy concerning correction of brain pathological changes during ischemia, and particularly pharmacotherapy’ advantages using L-arginine have been analyzed. A  main attention paid to clinico-pharmacological effects of drug Tivomax, and possibilities of pathogenetically grounding of angioprotection and neuroprotection. A clinical efficacy of Mexiprim and peculiarities of it’s dosage regimen’s have been looked in detail.

##plugins.themes.bootstrap3.article.details##

How to Cite
Бурчинський, С. Г. (2017). Angioprotection: brain vessels’ protection in family medicine’s practice. Family Medicine, (5(73), 57–58. https://doi.org/10.30841/2307-5112.5(73).2017.123019
Issue
No. 5(73) (2017)
Section
For practicing physicians
Copyright (c) 2020 С. Г. Бурчинський

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.

Author Biography

С. Г. Бурчинський, ГУ «Институт геронтологии имени Д.Ф. Чеботарева НАМН Украины», г. Киев

S.G. Burchinsky

References

Бабушкина А.В. L-аргинин с точки зрения доказательной медицины // Укр. мед. часопис. – 2009. – No 6. – С. 43–48.

Калашников В.И. Диагностика и коррекция эндотелиальной дисфункции у пациентов с дисциркуляторной энцефалопатией // Здоров’я України. – 2017. – No 2. – С. 27–28.

Мищенко Т.С. Эпидемиология цереброваскулярных заболеваний и организация помощи больным с мозговым инсультом в Украине // Укр. вісн. психоневрол. – 2017. – Т. 25, вип. 1. – С. 22–24.

Товажнянская Е.Л. Эндотелиальная дисфункция. Клинические аспекты проблемы и пути ее решения // Журн. неврол. им. Н.Б. Маньковского. – 2016. – No 3. – С. 17–21.

Трещинская М.А. Теоретические и практические аспекты применения L аргинина с целью профилактики цереброваскулярной патологии // Укр. мед. часопис. – 2011. – No 5. – С. 97–109.

Boger R.H. The pharmacodynamics of L-arginine // J. Nutr. – 2007. – V. 137. – P. 1650S–1655S.

Briasoulis A., Tousoulis D., Androulakis E.S. et al. Endothelial dysfunction and atherosclerosis: focus on novel therapeutic approaches // Recent Pat. Cardiovasc. Drug Discov. – 2012. – V. 7. – P. 21–32.

Cooke J.P. The endothelium: a new target for therapy // Vasc. Med. – 2000. – V. 5. – P. 49–53.

Loscalzo J. L arginine and atherotrombosis // J. Nutr. – 2004. – V. 134. – P. 2896–2897.

Lyons C.R. The role of nitric oxide in inflammation // Adv. Immunol. – 1995. – V. 60. – P. 323–371.